Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022

The inducement grants consisted of non-statutory stock options to purchase an aggregate of 370,100 shares of the Company’s common stock and an aggregate of 18,700 restricted stock units for shares of the Company’s common stock.

The stock options each have an exercise price of $17.79 per share, equal to the closing price of Iveric Bio’s common stock on April 1, 2022. The stock options each have a ten-year term and vest over four years, with 25% of the shares underlying each option vesting on April 1, 2023 and an additional 2.0833% of the shares underlying each option vesting at the end of each successive month thereafter. A tranche of 2,500 restricted stock units vests with respect to 100% of the shares underlying the units on July 1, 2022. A tranche of 200 restricted stock units vests with respect to 100% of the shares underlying the units on September 1, 2022. A tranche of 14,500 restricted stock units vests with respect to 50% of the shares underlying the applicable units on September 1, 2022 and the remaining 50% of the shares underlying the applicable units on April 1, 2023. A tranche of 1,500 restricted stock units vests with respect to 25% of the shares underlying the units on each of April 1, 2023, April 1, 2024, April 1, 2025 and April 1, 2026. The vesting of the grants is subject to the applicable employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005504/en/